Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 6/20 | 0.33 |
| ▸ | PPARA | Q07869 | 6/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1377219 | 1.00 | LMNA (0.35) | LMNAL3MBTL1PDE4ATDP1MTNR1A | |
| SCHEMBL5822045 | 1.00 | LMNA (0.35) | LMNAL3MBTL1PDE4ATDP1MTNR1A | |
| SCHEMBL7913872 | 0.86 | APP (0.35) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL9191589 | 0.86 | APP (0.35) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL8593832 | 0.86 | LMNA (0.34) | LMNAL3MBTL1PDE4ATDP1 | |
| SCHEMBL707743 | 0.80 | MEN1 (0.42) | LMNATDP1MAPTALDH1A1 | |
| SCHEMBL8603750 | 0.80 | MEN1 (0.42) | LMNATDP1MAPTALDH1A1 | |
| SCHEMBL1582160 | 0.80 | MEN1 (0.42) | LMNATDP1MAPTALDH1A1 | |
| SCHEMBL9634744 | 0.80 | MEN1 (0.42) | LMNATDP1MAPTALDH1A1 | |
| SCHEMBL7755252 | 0.79 | EPHX1 (0.32) | LMNAL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220049260-A1 | INDUCIBLE EXPRESSION SYSTEM FOR PLASMID-FREE PRODUCTION OF A PROTEIN OF INTEREST | BOEHRINGER INGELHEIM RCV GMBH & CO. KG (AT) | 2022-02-17 | — | — | US | claimed |
| US-8623652-B2 | Host-vector system for cloning and expressing genes | LUCIGEN CORPORATION (US) | 2014-01-07 | — | — | US | claimed |
| US-20100255561-A1 | HOST-VECTOR SYSTEM FOR CLONING AND EXPRESSING GENES | LUCIGEN CORPORATION | 2010-10-07 | — | — | US | claimed |
| US-20250319032-A1 | PHARMACEUTICAL COMPOSITIONS OF RIBOCICLIB | NOVARTIS FARMACEVTSKA PROIZVODNJA D.O.O. (SI) | 2025-10-16 | — | — | US | disclosed |
| US-20220049260-A1 | INDUCIBLE EXPRESSION SYSTEM FOR PLASMID-FREE PRODUCTION OF A PROTEIN OF INTEREST | BOEHRINGER INGELHEIM RCV GMBH & CO. KG (AT) | 2022-02-17 | — | — | US | disclosed |
| EP-2655648-B1 | GENETICALLY ENGINEERED MICROORGANISMS COMPRISING 4-HYDROXYBENZOYL-COA THIOESTERASES, METHODS OF USING THE SAME FOR PRODUCING FREE FATTY ACIDS AND FATTY ACID DERIVATIVES AND 4-HYDROXYBENZOYL-COA THIOESTERASES | EXXONMOBIL RES & ENG CO (US) | 2018-01-17 | — | — | EP | disclosed |
| US-8623652-B2 | Host-vector system for cloning and expressing genes | LUCIGEN CORPORATION (US) | 2014-01-07 | — | — | US | disclosed |
| US-8530207-B2 | Photosynthetic microorganisms comprising exogenous prokaryotic acyl-ACP thioesterases and methods for producing fatty acids | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120164700-A1 | PROKARYOTIC ACYL-ACP THIOESTERASES FOR PRODUCING FATTY ACIDS IN GENETICALLY ENGINEERED MICROORGANISMS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120164713-A1 | GENETICALLY ENGINEERED MICROORGANISMS COMPRISING 4-HYDROXYBENZOYL-COA THIOESTERASES AND METHODS OF USING THE SAME FOR PRODUCING FREE FATTY ACIDS AND FATTY ACID DERIVATIVES | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2012-06-28 | — | — | US | disclosed |
| US-20100255561-A1 | HOST-VECTOR SYSTEM FOR CLONING AND EXPRESSING GENES | LUCIGEN CORPORATION | 2010-10-07 | — | — | US | disclosed |
| EP-1006797-A1 | SERPIN ENZYME COMPLEX RECEPTOR-MEDIATED GENE TRANSFER | Case Western Reserve University (US) | 2000-06-14 | — | — | EP | disclosed |
| US-6008336-A | Compacted nucleic acids and their delivery to cells | CASE WESTERN RESERVE UNIVERSITY (US) | 1999-12-28 | — | — | US | disclosed |
| US-5972901-A | MAKING A COMPOSITION FOR DELIVERING AN OLIGONUCLEOTIDE TO A MAMMALIAN CELL BY PROVIDING A PEPTIDE TARGET BINDING MOIETY BEING CAPABLE OF BINDING TO A SERPIN ENZYME COMPLEX RECEPTOR, POLYLYSINE, AN OLIGONUCLEOTIDE VECTOR; CONJUGATING, COUPLING | CASE WESTERN RESERVE UNIVERSITY (US) | 1999-10-26 | — | — | US | disclosed |
| US-5972900-A | CONJUGATING TARGET BINDING MOIETY CONSISTING OF AN ANTIBODY OR FRAGMENT WHICH BINDS TO SECRETORY COMPONENT OF POLYMERIC IMMUNOGLOBULIN RECEPTOR ON SURFACE OF EPITHELIUM CELL, NUCLEIC ACID BINDER, EXPRESSION VECTOR, COMPACTING, ADMINISTERING | CASE WESTERN RESERVE UNIVERSITY (US) | 1999-10-26 | — | — | US | disclosed |
| US-5877302-A | UNAGGREGATED COMPLEXES OF SINGLE NUCLEIC ACID MOLECULE AND ONE OR MORE CARRIER MOLECULES WITH NUCLEIC ACID BINDING MOIETY AND TARGET CELL BINDING MOIETY; FOR TARGETED GENE THERAPY | CASE WESTERN RESERVE UNIVERSITY (US) | 1999-03-02 | — | — | US | disclosed |
| US-5844107-A | Compacted nucleic acids and their delivery to cells | CASE WESTERN RESERVE UNIVERSITY (US) | 1998-12-01 | — | — | US | disclosed |
| WO-1997046100-A1 | SERPIN ENZYME COMPLEX RECEPTOR-MEDIATED GENE TRANSFER | CASE WESTERN RESERVE UNIVERSITY (US) | 1997-12-11 | — | — | WO | disclosed |
| EP-0752005-A1 | COMPACTED NUCLEIC ACIDS AND THEIR DELIVERY TO CELLS | OHIO UNIVERSITY (US) | 1997-01-08 | — | — | EP | disclosed |
| WO-1995025809-A1 | COMPACTED NUCLEIC ACIDS AND THEIR DELIVERY TO CELLS | OHIO UNIVERSITY (US) | 1995-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319032-A1 | PHARMACEUTICAL COMPOSITIONS OF RIBOCICLIB | NRAS, NSUN2, RTCB | LMNA 2198/4885L3MBTL1 4341/4885PDE4A 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.